2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study

BACKGROUND: LET is a CMV DNA terminase complex inhibitor approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic HCT recipients. This study evaluated PK, safety and efficacy of LET for CMV prophylaxis in pediatric allogeneic HCT recipients. METHODS: This was a Phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulte, Johannes H, Gefen, Aharon, Groll, Andreas H, Fraser, Christopher J, Teal, Valerie L, Haber, Barbara A, Gilbert, Christopher L, McCrea, Jacqueline B, Patel, Mayankbhai, Menzel, Karsten, Badshah, Cyrus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679196/
http://dx.doi.org/10.1093/ofid/ofad500.2180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679196/
http://dx.doi.org/10.1093/ofid/ofad500.2180

Ejemplares similares